LEO Pharma invests in Novopyxis to develop an aerosol-based drug delivery device for topical treatments
(WorldNews Denmark)

BALLERUP, Denmark and CAMBRIDGE, USA, 21 June 2017 - LEO Pharma announces an investment in the biotechnology company Novopyxis to support the development of an early-stage drug delivery device designed to increase the penetration of topical treatments in the skin. The hand-held aerosol device will be clinically tested on people with alopecia, where there is a high need for alternative treatment options to painful steroid injections. Alopecia is an...